CRDF Q3 2017 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$137M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$123,329+38.4% YoY

Gross Profit

-$349,873-283.7% margin

Operating Income

-$6M-4700.9% margin

Net Income

-$4M-3480.1% margin

EPS (Diluted)

$-8.47

QoQ Revenue Growth

+20.9%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$12M

Total Liabilities

$8M

Stockholders' Equity

$4M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$123,329	$89,114	+38.4%
Gross Profit	-$349,873	-$335,445	-4.3%
Operating Income	-$6M	-$10M	+41.6%
Net Income	-$4M	-$10M	+57.9%